As the industry awaits official word from the administration on how the tariffs will hit, analysts go over the possibilities ...

The National Security Commission on Emerging Biotechnology recommends at least a $15 billion investment into biotech over the ...

The FDA approved the use of Opdivo with Yervoy in front-line colorectal cancer, while a Manhattan court junked a class action ...

Jazz is being accused of anti-competitive practices regarding its narcolepsy drug, as generic competitors emerge on the ...

Analysts suggested that the tariffs will have little effect on reshoring manufacturing and will likely decrease patient drug access and increase costs.

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Billions in market cap are being shed as the markets reel over President Donald Trump’s escalating trade war. Eli Lilly’s ...

A consumer-driven weight loss market could put pharma at greater risk if a recession hits; the continued turmoil at FDA and other HHS agencies magnifies the uncertainty facing the industry; Lilly ...

Long considered resistant to economic downturns, the pharmaceutical industry may face a greater challenge this time around as ...

The Trump administration reversed a Biden-era proposal for Medicare coverage of anti-obesity treatments. But on Monday, HHS ...

The company is dropping its former lead molecule in favor of another antibody, RLYB116, which is being developed for a ...

Merida is working on a selective therapy for Graves’ disease, leveraging targeted therapies that can deplete disease-causing ...